Comparison · incumbent feasibility & intelligence vendor
A cited, auditable Citeline alternative.
Citeline (Norstella) is a deep, well-established intelligence suite. If what you need from feasibility is a fast, fully-cited, re-runnable verdict you can white-label into a bid and defend line by line, here is how we compare.
Side by side
Citeline vs Clinical Trial OS.
The dimensions that decide a feasibility answer, on one row each. Our column is the emphasised one.
| Capability | Citeline | Clinical Trial OS |
|---|---|---|
| Typical turnaround per protocol | Varies (often days to weeks) | Hours |
| Every number cited to a public source | Varies | Yes |
| Same inputs, same verdict — reproducible months later | Varies | Yes |
| 21 CFR Part 11 tamper-evident audit chain on every run | Varies | Yes |
| White-label + dedicated single-tenant cluster | Varies | Yes |
| Private EU-region inference — protocols never used to train a third-party model | Varies | Yes |
| Pricing model | Enterprise / subscription | Per-run + platform plan |
- Yes
- Varies by engagement
- No
The honest read
What they do well, and what we do differently.
Where Citeline is strong
Citeline brings a large proprietary intelligence dataset, investigator and site databases, and a long track record across the industry. For broad market intelligence beyond a single feasibility verdict, that breadth is real.
Where we differ
- Every figure in the verdict links to its public-source record (ClinicalTrials.gov, AACT, PubMed, FDA, EMA, Open Targets, ChEMBL) with a snapshot date — not a proprietary black box.
- Reproducible by design: the same inputs and snapshot produce the same verdict months later, which is what makes it defensible in a sponsor review.
- A 21 CFR Part 11 tamper-evident audit bundle on every run, exportable for your QA team.
- White-label and dedicated-cluster mode so a CRO can resell the output under its own brand.
This comparison reflects our understanding of typical offerings and is provided in good faith; vendor capabilities change, so verify current details with each provider. All product names, logos, and trademarks are the property of their respective owners and are used for identification only.
Other comparisons
See a cited verdict against your own protocol.
Send us a protocol — or just a molecule and an indication. We'll return a fully cited feasibility assessment you can trace, line by line, back to public data — yours to defend in a bid, take to your board or investment committee, or hand to a regulator.